Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade

Molecular Therapy Oncolytics

Volumn 4, Issue , 2017, Pages 41-54

  Serganova, Inna ^a   Moroz, Ekaterina ^a   Cohen, Ivan ^b   Moroz, Maxim ^a   Mane, Mayuresh ^a   Zurita, Juan ^a   Shenker, Larissa ^a   Ponomarev, Vladimir ^a   Blasberg, Ronald ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Gerstner Sloan Kettering Graduate School of Biomedical Sciences   (United States)

Author keywords

anti PD1; bioluminescence imaging; BLI; CAR T cells; human PSMA; luciferase reporters; prostate cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD31 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LUCIFERASE; LUCIFERIN; MONOCLONAL ANTIBODY; MYC PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER SIZE; CAPILLARY DENSITY; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE;

EID: 85020543769     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1016/j.omto.2016.11.005     Document Type: Article

References (89)

1. 1 Hsing, A.W., Tsao, L., Devesa, S.S., International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85 (2000), 60–67.
2. 2 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 65 (2015), 5–29.
3. 3 Ning, Y.M., Gulley, J.L., Arlen, P.M., Woo, S., Steinberg, S.M., Wright, J.J., Parnes, H.L., Trepel, J.B., Lee, M.J., Kim, Y.S., et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28 (2010), 2070–2076.
4. 4 Clarke, J.M., Armstrong, A.J., Novel therapies for the treatment of advanced prostate cancer. Curr. Treat. Options Oncol. 14 (2013), 109–126.
5. 5 DiPaola, R.S., Plante, M., Kaufman, H., Petrylak, D.P., Israeli, R., Lattime, E., Manson, K., Schuetz, T., A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J. Transl. Med., 4, 2006, 1.
6. 6 Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (2010), 411–422.
7. 7 Hillerdal, V., Essand, M., Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs 29 (2015), 75–89.
8. 8 Sadelain, M., Rivière, I., Brentjens, R., Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3 (2003), 35–45.
9. 9 Sadelain, M., T-cell engineering for cancer immunotherapy. Cancer J. 15 (2009), 451–455.
10. 10 Morello, A., Sadelain, M., Adusumilli, P.S., Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 6 (2016), 133–146.
11. 11 Geiger, T.L., Jyothi, M.D., Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfus. Med. Rev. 15 (2001), 21–34.
12. 12 Ma, Q., Gonzalo-Daganzo, R.M., Junghans, R.P., Genetically engineered T cells as adoptive immunotherapy of cancer. Cancer Chemother. Biol. Response Modif. 20 (2002), 315–341.
13. 13 Altenschmidt, U., Klundt, E., Groner, B., Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J. Immunol. 159 (1997), 5509–5515.
14. 14 Darcy, P.K., Haynes, N.M., Snook, M.B., Trapani, J.A., Cerruti, L., Jane, S.M., Smyth, M.J., Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J. Immunol. 164 (2000), 3705–3712.
15. 15 Haynes, N.M., Trapani, J.A., Teng, M.W., Jackson, J.T., Cerruti, L., Jane, S.M., Kershaw, M.H., Smyth, M.J., Darcy, P.K., Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100 (2002), 3155–3163.
16. 16 McGuinness, R.P., Ge, Y., Patel, S.D., Kashmiri, S.V., Lee, H.S., Hand, P.H., Schlom, J., Finer, M.H., McArthur, J.G., Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum. Gene Ther. 10 (1999), 165–173.
17. 17 Hwu, P., Yang, J.C., Cowherd, R., Treisman, J., Shafer, G.E., Eshhar, Z., Rosenberg, S.A., In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55 (1995), 3369–3373.
18. 18 Wang, G., Chopra, R.K., Royal, R.E., Yang, J.C., Rosenberg, S.A., Hwu, P., A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat. Med. 4 (1998), 168–172.
19. 19 Chekmasova, A.A., Rao, T.D., Nikhamin, Y., Park, K.J., Levine, D.A., Spriggs, D.R., Brentjens, R.J., Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16 (2010), 3594–3606.
20. 20 Brentjens, R.J., Latouche, J.B., Santos, E., Marti, F., Gong, M.C., Lyddane, C., King, P.D., Larson, S., Weiss, M., Rivière, I., Sadelain, M., Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9 (2003), 279–286.
21. 21 Gade, T.P., Hassen, W., Santos, E., Gunset, G., Saudemont, A., Gong, M.C., Brentjens, R., Zhong, X.S., Stephan, M., Stefanski, J., et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65 (2005), 9080–9088.
22. 22 Adusumilli, P.S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D.R., Sadelain, M., Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med., 6, 2014, 261ra151.
23. 23 Sweat, S.D., Pacelli, A., Murphy, G.P., Bostwick, D.G., Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52 (1998), 637–640.
24. 24 Dobrenkov, K., Olszewska, M., Likar, Y., Shenker, L., Gunset, G., Cai, S., Pillarsetty, N., Hricak, H., Sadelain, M., Ponomarev, V., Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 49 (2008), 1162–1170.
25. 25 Likar, Y., Dobrenkov, K., Olszewska, M., Shenker, L., Cai, S., Hricak, H., Ponomarev, V., PET imaging of HSV1-tk mutants with acquired specificity toward pyrimidine- and acycloguanosine-based radiotracers. Eur. J. Nucl. Med. Mol. Imaging 36 (2009), 1273–1282.
26. 26 Baiz, D., Hassan, S., Choi, Y.A., Flores, A., Karpova, Y., Yancey, D., Pullikuth, A., Sui, G., Sadelain, M., Debinski, W., Kulik, G., Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia 15 (2013), 1172–1183.
27. 27 Gong, M.C., Chang, S.S., Sadelain, M., Bander, N.H., Heston, W.D., Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 18 (1999), 483–490.
28. 28 Gong, M.C., Latouche, J.B., Krause, A., Heston, W.D., Bander, N.H., Sadelain, M., Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1 (1999), 123–127.
29. 29 Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 2013, 177ra38.
30. 30 Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
31. 31 Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X., James, S.E., Raubitschek, A., Forman, S.J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112 (2008), 2261–2271.
32. 32 Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14 (2008), 1264–1270.
33. 33 Peres, E., Wood, G.W., Poulik, J., Baynes, R., Sood, S., Abidi, M.H., Klein, J., Bhambhani, K., Dansey, R., Abella, E., High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 39 (2008), 151–156.
34. 34 Gilham, D.E., Debets, R., Pule, M., Hawkins, R.E., Abken, H., CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 18 (2012), 377–384.
35. 35 Gajewski, T.F., Woo, S.R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., Spranger, S., Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25 (2013), 268–276.
36. 36 Fearon, D.T., The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2 (2014), 187–193.
37. 37 Peng, W., Ye, Y., Rabinovich, B.A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W.W., Lizée, G., Hwu, P., Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 16 (2010), 5458–5468.
38. 38 Zhang, L., Morgan, R.A., Beane, J.D., Zheng, Z., Dudley, M.E., Kassim, S.H., Nahvi, A.V., Ngo, L.T., Sherry, R.M., Phan, G.Q., et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 21 (2015), 2278–2288.
39. 39 Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P.T., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33 (2015), 540–549.
40. 40 Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D.S., Jones, D.R., Sadelain, M., Adusumilli, P.S., Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126 (2016), 3130–3144.
41. 41 Stephan, S.B., Taber, A.M., Jileaeva, I., Pegues, E.P., Sentman, C.L., Stephan, M.T., Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Biotechnol. 33 (2015), 97–101.
42. 42 Roth, T.J., Sheinin, Y., Lohse, C.M., Kuntz, S.M., Frigola, X., Inman, B.A., Krambeck, A.E., McKenney, M.E., Karnes, R.J., Blute, M.L., et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67 (2007), 7893–7900.
43. 43 Martin, A.M., Nirschl, T.R., Nirschl, C.J., Francica, B.J., Kochel, C.M., van Bokhoven, A., Meeker, A.K., Lucia, M.S., Anders, R.A., DeMarzo, A.M., Drake, C.G., Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 18 (2015), 325–332.
44. 44 Ebelt, K., Babaryka, G., Frankenberger, B., Stief, C.G., Eisenmenger, W., Kirchner, T., Schendel, D.J., Noessner, E., Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur. J. Cancer 45 (2009), 1664–1672.
45. 45 Gevensleben, H., Dietrich, D., Golletz, C., Steiner, S., Jung, M., Thiesler, T., Majores, M., Stein, J., Uhl, B., Müller, S., et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res. 22 (2015), 1969–1977.
46. 46 Momtaz, P., Postow, M.A., Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharm. Genomics Pers. Med. 7 (2014), 357–365.
47. 47 Callahan, M.K., Wolchok, J.D., At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol. 94 (2013), 41–53.
48. 48 Zhong, X.S., Matsushita, M., Plotkin, J., Riviere, I., Sadelain, M., Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18 (2010), 413–420.
49. 49 Zuccolotto, G., Fracasso, G., Merlo, A., Montagner, I.M., Rondina, M., Bobisse, S., Figini, M., Cingarlini, S., Colombatti, M., Zanovello, P., Rosato, A., PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS ONE, 9, 2014, e109427.
50. 50 Watson, P.A., Ellwood-Yen, K., King, J.C., Wongvipat, J., Lebeau, M.M., Sawyers, C.L., Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 65 (2005), 11565–11571.
51. 51 Rivière, I., Brose, K., Mulligan, R.C., Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92 (1995), 6733–6737.
52. 52 Ponomarev, V., Doubrovin, M., Serganova, I., Beresten, T., Vider, J., Shavrin, A., Ageyeva, L., Balatoni, J., Blasberg, R., Tjuvajev, J.G., Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging. Neoplasia 5 (2003), 245–254.
53. 53 Maher, J., Brentjens, R.J., Gunset, G., Rivière, I., Sadelain, M., Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20 (2002), 70–75.
54. 54 Huang, R., Vider, J., Serganova, I., Blasberg, R.G., ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging. Mol. Imaging 10 (2011), 215–226.
55. 55 Genovesi, E.V., Pettey, C.L., Collins, J.J., Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy. Cancer Res. 44 (1984), 1489–1498.
56. 56 Morán, M., Rivera, H., Sánchez-Aragó, M., Blázquez, A., Merinero, B., Ugalde, C., Arenas, J., Cuezva, J.M., Martín, M.A., Mitochondrial bioenergetics and dynamics interplay in complex I-deficient fibroblasts. Biochim. Biophys. Acta 1802 (2010), 443–453.
57. 57 Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
58. 58 Kochenderfer, J.N., Rosenberg, S.A., Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10 (2013), 267–276.
59. 59 Tsushima, F., Yao, S., Shin, T., Flies, A., Flies, S., Xu, H., Tamada, K., Pardoll, D.M., Chen, L., Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110 (2007), 180–185.
60. 60 Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20 (2014), 5064–5074.
61. 61 Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
62. 62 Jiang, Y., Li, Y., Zhu, B., T-cell exhaustion in the tumor microenvironment. Cell Death Dis., 6, 2015, e1792.
63. 63 Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
64. 64 June, C.H., Ledbetter, J.A., Gillespie, M.M., Lindsten, T., Thompson, C.B., T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7 (1987), 4472–4481.
65. 65 Teague, T.K., Munn, L., Zygourakis, K., McIntyre, B.W., Analysis of lymphocyte activation and proliferation by video microscopy and digital imaging. Cytometry 14 (1993), 772–782.
66. 66 Moon, E.K., Ranganathan, R., Eruslanov, E., Kim, S., Newick, K., O'Brien, S., Lo, A., Liu, X., Zhao, Y., Albelda, S.M., Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin. Cancer Res. 22 (2016), 436–447.
67. 67 Shi, H., Sun, M., Liu, L., Wang, Z., Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol. Cancer, 13, 2014, 219.
68. 68 Brentjens, R.J., Rivière, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828.
69. 69 Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., Marcucci, K.T., Shen, A., Gonzalez, V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med., 7, 2015, 303ra139.
70. 70 Maude, S.L., Teachey, D.T., Porter, D.L., Grupp, S.A., CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125 (2015), 4017–4023.
71. 71 Anurathapan, U., Chan, R.C., Hindi, H.F., Mucharla, R., Bajgain, P., Hayes, B.C., Fisher, W.E., Heslop, H.E., Rooney, C.M., Brenner, M.K., et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol. Ther. 22 (2014), 623–633.
72. 72 Robbins, P.F., Dudley, M.E., Wunderlich, J., El-Gamil, M., Li, Y.F., Zhou, J., Huang, J., Powell, D.J. Jr., Rosenberg, S.A., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173 (2004), 7125–7130.
73. 73 Kakarla, S., Gottschalk, S., CAR T cells for solid tumors: armed and ready to go?. Cancer J. 20 (2014), 151–155.
74. 74 Fox, C.J., Hammerman, P.S., Thompson, C.B., Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5 (2005), 844–852.
75. 75 Frauwirth, K.A., Thompson, C.B., Regulation of T lymphocyte metabolism. J. Immunol. 172 (2004), 4661–4665.
76. 76 Scharping, N.E., Menk, A.V., Moreci, R.S., Whetstone, R.D., Dadey, R.E., Watkins, S.C., Ferris, R.L., Delgoffe, G.M., The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45 (2016), 374–388.
77. 77 Thorne, N., Inglese, J., Auld, D.S., Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem. Biol. 17 (2010), 646–657.
78. 78 Cao, Y.A., Bachmann, M.H., Beilhack, A., Yang, Y., Tanaka, M., Swijnenburg, R.J., Reeves, R., Taylor-Edwards, C., Schulz, S., Doyle, T.C., et al. Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation 80 (2005), 134–139.
79. 79 Santos, E.B., Yeh, R., Lee, J., Nikhamin, Y., Punzalan, B., Punzalan, B., La Perle, K., Larson, S.M., Sadelain, M., Brentjens, R.J., Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat. Med. 15 (2009), 338–344.
80. 80 Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000), 1027–1034.
81. 81 Zhang, X., Schwartz, J.C.D., Guo, X., Bhatia, S., Cao, E., Lorenz, M., Cammer, M., Chen, L., Zhang, Z.Y., Edidin, M.A., et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20 (2004), 337–347.
82. 82 Lin, D.Y., Tanaka, Y., Iwasaki, M., Gittis, A.G., Su, H.P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., Garboczi, D.N., The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. USA 105 (2008), 3011–3016.
83. 83 Lázár-Molnár, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S.G., Almo, S.C., Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc. Natl. Acad. Sci. USA 105 (2008), 10483–10488.
84. 84 Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L.C., Muskett, F.W., Morgan, S.H., Huo, J., Yu, C., Evans, E.J., Leslie, A.J., et al. Structure and interactions of the human programmed cell death 1 receptor. J. Biol. Chem. 288 (2013), 11771–11785.
85. 85 John, L.B., Devaud, C., Duong, C.P., Yong, C.S., Beavis, P.A., Haynes, N.M., Chow, M.T., Smyth, M.J., Kershaw, M.H., Darcy, P.K., Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 19 (2013), 5636–5646.
86. 86 Hombach, A., Schneider, C., Sent, D., Koch, D., Willemsen, R.A., Diehl, V., Kruis, W., Bolhuis, R.L., Pohl, C., Abken, H., An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int. J. Cancer 88 (2000), 115–120.
87. 87 Wang, X., Rivière, I., Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 22 (2015), 85–94.
88. 88 Serganova, I., Rizwan, A., Ni, X., Thakur, S.B., Vider, J., Russell, J., Blasberg, R., Koutcher, J.A., Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype. Clin. Cancer Res. 17 (2011), 6250–6261.
89. 89 Moroz, E., Carlin, S., Dyomina, K., Burke, S., Thaler, H.T., Blasberg, R., Serganova, I., Real-time imaging of HIF-1alpha stabilization and degradation. PLoS ONE, 4, 2009, e5077.